Related Experiment Video
Updated: Jul 8, 2025
08:13
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
4.7K
SIRPα controls CD47-dependent platelet clearance in mice and humans
Maia Shoham1,2, Ying Ying Yiu1,2, Paige S Hansen1,3
1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Biorxiv : the Preprint Server for Biology
|December 18, 2023
Summary
The CD47-SIRPα pathway regulates platelet clearance. Blocking this pathway impacts platelet levels, and variations in SIRPA gene expression influence platelet counts and anti-CD47 therapy outcomes.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- CD47 protein on cancer cells mediates immune evasion and tumor progression.
- CD47 binding to SIRPα inhibits phagocytosis, impacting cell clearance.
- CD47 blockade is a promising immuno-oncology therapy but can cause thrombocytopenia.
Conclusions:
- The CD47-SIRPα axis is crucial for platelet homeostasis.
- Understanding SIRPA variations is important for predicting anti-CD47 therapy side effects.
- Targeting the CD47-SIRPα pathway requires careful consideration of platelet level regulation.
